[go: up one dir, main page]

EP3585785B1 - Process for the preparation of methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h-1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylate - Google Patents

Process for the preparation of methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h-1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylate Download PDF

Info

Publication number
EP3585785B1
EP3585785B1 EP18706467.0A EP18706467A EP3585785B1 EP 3585785 B1 EP3585785 B1 EP 3585785B1 EP 18706467 A EP18706467 A EP 18706467A EP 3585785 B1 EP3585785 B1 EP 3585785B1
Authority
EP
European Patent Office
Prior art keywords
methyl
formula
reaction
dihydro
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP18706467.0A
Other languages
German (de)
French (fr)
Other versions
EP3585785A1 (en
Inventor
Sergii Pazenok
Christian Funke
Friedrich August MÜHLTHAU
Mark James Ford
Arnd Neeff
Klaus-Ulrich SCHIFFER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Bayer CropScience AG
Original Assignee
Bayer AG
Bayer CropScience AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer CropScience AG filed Critical Bayer AG
Publication of EP3585785A1 publication Critical patent/EP3585785A1/en
Application granted granted Critical
Publication of EP3585785B1 publication Critical patent/EP3585785B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A01N43/06Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom five-membered rings
    • A01N43/10Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom five-membered rings with sulfur as the ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms

Definitions

  • the invention relates to an improved process for the preparation of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl ] -5-methylthiophene-3-carboxylate (known under the common name "Thiencarbazone-methyl”).
  • Selected substituted thien-3-yl-sulfonylamino-carbonyltriazolinones such as thiencarbazone-methyl, have a particularly good herbicidal effect.
  • reaction auxiliaries disclosed relate to acid binders which can usually be used for such reactions.
  • the on page 9 of DE 19933260 A1 mentioned selection also includes potassium tert-butoxide and basic nitrogen compounds such as amines including tributylamine and pyridines such as 2-methylpyridines, 3-methylpyridines, 5-ethyl-2-methylpyridines, 2,6-dimethylpyridines.
  • the object of the invention is to provide an improved process for the preparation of substituted thien-3yl-sulfonylamino-carbonyltriazolinones, in particular thiencarbazone-methyl, ie the compound of the formula (I), the improved process being the preparation of the target compound thiencarbazone -methyl should enable high purity and yield.
  • the object is achieved by the process according to claim 1 for the preparation of the compound of the formula (I) by reacting the compound of formula (II) with a metal cyanate of the formula (III) MeOCN (III) where Me stands for Li, Na, K or, Cs with the compound of formula (IV) , where the reaction in the presence of an imidazole of the formula (V) , in which the radical R1 is an unsubstituted (C 1 -C 12 ) -alkyl or an unsubstituted benzyl.
  • the invention is thus based on the finding that the compound of the formula (I) thiencarbazone-methyl under certain conditions, namely in the presence of an imidazole base substituted in the 1-position or in the presence of a base mixture which has a 1-position substituted imidazole base (N-alkylimidazole) contains, can be prepared directly from 4-methoxycarbonyl-2-methyl-thiophene-3-sulfonic acid chloride (compound of formula (II)) with a high purity and yield.
  • the above reaction scheme shows that when the reaction is carried out as a one-pot synthesis, a 4-component system is present at the start of the reaction.
  • the core of the present invention relates to the surprising finding that the metal cyanate with the sulfonyl group of the respective thiophene compound (in the above scheme with the methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate of the formula (II)) in the presence of an N-alkylimidazole of the formula (V) reacts selectively to form a sulfonyl isocyanate, and that the substituted thien-3yl-sulfonylamino-carbonyltriazolinone (in the above reaction scheme, the target compound thiencarbazone-methyl (I)) is then formed from this.
  • the unexpected selectivity of the reaction shown in the scheme consists in the fact that the triazolinone (IV) only reacts further with the sulfonyl isocyanate to form thiencarbazone-methyl after formation of the sulfonyl isocyanate.
  • metal cyanates are strong bases (sodium cyanate (NaOCN), for example, has a pH of 10). At the same time, metal cyanates act as O nucleophiles.
  • the O-nucleophilicity of the metal cyanates used according to the invention surprisingly has no effect on the course of the present reaction, i.e. its yield and selectivity.
  • N-methylimidazole N-methylimidazole
  • the reagents are preferably used in equimolar amounts or in excess.
  • Me in compounds of the formula MeOCN (III) stands for Na or for K.
  • the most preferred metal cyanate in the process according to the invention is NaOCN.
  • per mole of sulfonic acid chloride, ie of the compound of the formula (IV) there are also 1 to 2 Mol, preferably 1 to 1.5 mol, particularly preferably 1 to 1.1 mol.
  • the process is carried out in an organic solvent, with non-polar and polar solvents being suitable.
  • Suitable non-polar solvents are toluene, chlorobenzene, xylene, methyl tert-butyl ether, methyl isopropyl ether, ethyl acetate, isopropyl acetate and butyl acetate.
  • Particularly preferred polar solvents are selected from the group consisting of acetonitrile, butyronitrile, tetrahydrofuran (THF), methyl-THF, dimethoxyethane, sulfolane, dimethylformamide and dimethylacetamide.
  • Most preferred solvents are acetonitrile and THF.
  • the reactants are preferably reacted in a temperature range from 20 ° to 110 ° over a period (reaction time, reaction time) of 3 hours to 24 hours.
  • the reaction of the starting materials in a temperature range from 30 ° to 90 ° is very particularly preferred. Most preferably, the reactants are reacted in a temperature range from 50 ° to 80 °.
  • Another aspect of the invention relates to the use of an imidazole of the formula (V) , in which the radical R 1 is an unsubstituted (C 1 -C 12 ) -alkyl or an unsubstituted benzyl, for the preparation of the compound of the formula (I)
  • R 1 is an unbranched and unsubstituted (C 1 -C 4 ) -alkyl, ie, methyl, ethyl, n-propyl or n-butyl.
  • the production process according to the invention can be carried out as a one-pot process or as a two-stage reaction.
  • the active ingredient or its salt precipitates out of the reaction mixture and can simply be filtered off.
  • an inorganic base such as LiOH, K 2 CO 3 , NaHCO 3 , NaOH, Na 2 CO 3 , CaCO 3 or KOH
  • an inorganic base such as LiOH, K 2 CO 3 , NaHCO 3 , NaOH, Na 2 CO 3 , CaCO 3 or KOH
  • the use of NaHCO 3 is preferred. In this way, the active ingredient can be isolated with a very high degree of purity.
  • the amount of base to be used depends on how much metal cyanate is used when carrying out the reaction. If only 1 equivalent (eq) of NaOCN is used, 1 eq. Of base is then required to completely convert the active ingredient into the salt (example 1). If you set for example 2 eq of the metal cyanate, for example 2 eq NaOCN, to carry out the reaction, no additional base is necessary (cf. Example 3).
  • the isocyanate can be isolated and purified by distillation in vacuo.
  • TABLE 1 Tabular comparison of the yields based on LC analysis when using different reaction auxiliaries for the preparation of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1 -yl) carbonyl) sulfamoyl] -5-methylthiophenes-3-carboxylate (thiencarbazone-methyl), in acetonitrile, NaOCN 2 eq. Comparison No.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Description

Die Erfindung betrifft ein verbessertes Verfahren zur Herstellung von Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylat (bekannt unter dem common name "Thiencarbazone-methyl").The invention relates to an improved process for the preparation of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl ] -5-methylthiophene-3-carboxylate (known under the common name "Thiencarbazone-methyl").

Die herbizide Wirkung von substituierten Thien-3-yl-sulfonylaminocarbonyl-triazolinonen ist aus dem Dokument DE 199 33 260 A1 und aus Dokument WO 01/05788 A1 , in welchem die Priorität der DE 199 33 260 A1 beansprucht wird, bekannt.The herbicidal effect of substituted thien-3-yl-sulfonylaminocarbonyl-triazolinones is from the document DE 199 33 260 A1 and from document WO 01/05788 A1 in which the priority of the DE 199 33 260 A1 is claimed is known.

Eine besonders gute herbizide Wirkung haben ausgewählte substituierte Thien-3-yl-sulfonylamino-carbonyltriazolinone, wie z.B. Thiencarbazone-methyl.Selected substituted thien-3-yl-sulfonylamino-carbonyltriazolinones, such as thiencarbazone-methyl, have a particularly good herbicidal effect.

Aufgrund der guten Wirkung wurde die Verbesserung der Verfahren zur Herstellung der vorgenannten Herbizide, auch im Hinblick auf die Umweltverträglichkeit der Herstellung, zu einem beständigen Bemühen der chemischen Forschung.Because of the good effect, the improvement of the processes for the production of the aforementioned herbicides, also with regard to the environmental compatibility of the production, has become a constant endeavor in chemical research.

Dokument DE 19933260 A1 offenbart, neben vier weiteren Verfahrensalternativen, mit der Alternative (c) ein Verfahren zur Herstellung von substituierten Thien-3-yl-sulfonylaminocarbonyl-triazolinonen durch Umsetzung von Sulfonylisocyanate mit 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on. Bei dieser vorgenannten Verfahrensalternative wird die Möglichkeit der Umsetzung von substituierten Thiophen-3-sulfonsäurechloriden mit substitutierten Triazolinonen und Metall(thio)cyanaten, gegebenenfalls in Gegenwart eines Reaktionshilfsmittels, und gegebenenfalls in Gegenwart eines Verdünnungsmittels lediglich durch ein Formelschema skizziert (vgl. DE 19933260 A1 , Seite 7), aber nicht durch ein ausgeführtes Beispiel belegt.document DE 19933260 A1 discloses, in addition to four other process alternatives, with alternative (c) a process for the preparation of substituted thien-3-yl-sulfonylaminocarbonyl-triazolinones by reacting sulfonyl isocyanates with 5-methoxy-4-methyl-2,4-dihydro-3H-1 , 2,4-triazol-3-one. In this alternative process mentioned above, the possibility of reacting substituted thiophene-3-sulfonic acid chlorides with substituted triazolinones and metal (thio) cyanates, optionally in the presence of a reaction auxiliary, and optionally in the presence of a diluent, is merely outlined by a formula scheme (cf. DE 19933260 A1 , Page 7), but not proven by an example.

Im Zusammenhang mit den Verfahrensalternativen (a) bis (e) werden in DE 19933260 A1 optionale Reaktionshilfsmittel offenbart. Diese betreffen für derartige Umsetzungen üblicherweise einsetzbare Säurebindemittel. Die auf Seite 9 von DE 19933260 A1 genannte Auswahl, umfasst auch Kalium-tert-butylat, sowie basische Stickstoffverbindungen, wie z.B. Amine darunter auch Tributylamin und Pyridine wie z.B. 2-Methylpyridine, 3-Methylpyridin, 5-Ethyl-2-methyl-pyridin, 2,6-Dimethylpyridin.In connection with the process alternatives (a) to (e), in DE 19933260 A1 optional reaction auxiliaries disclosed. These relate to acid binders which can usually be used for such reactions. The on page 9 of DE 19933260 A1 mentioned selection also includes potassium tert-butoxide and basic nitrogen compounds such as amines including tributylamine and pyridines such as 2-methylpyridines, 3-methylpyridines, 5-ethyl-2-methylpyridines, 2,6-dimethylpyridines.

Dagegen werden Imidazole in DE 19933260 A1 nicht als Reaktionshilfsmittel genannt.In contrast, imidazoles are used in DE 19933260 A1 not mentioned as a reaction aid.

In Dokument DE 10 2004 063192 A1 wird zur Herstellung des Sulfonylisocyanats, unter Anwendung der in DE 19933260 A1 offenbarten Verfahrensalternative (d.h. Herstellung von Thiencarbazone-methyl durch Umsetzung von Sulfonylisocyanate mit 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on) ein Verfahren ausgehend von Sulfonamid und Phosgen vorgeschlagen.In document DE 10 2004 063192 A1 is used to prepare the sulfonyl isocyanate, using the in DE 19933260 A1 disclosed process alternative (ie preparation of Thiencarbazone-methyl by reaction of sulfonyl isocyanate with 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one) proposed a process starting from sulfonamide and phosgene .

Jedoch ist das in DE 10 2004 063192 A1 offenbarte Verfahren, aufgrund der Verwendung von Phosgen, das als hochtoxisch eingestuft wird, gefährlich und somit aufwendig und teuer.However, this is in DE 10 2004 063192 A1 disclosed methods, due to the use of phosgene, which is classified as highly toxic, dangerous and thus complex and expensive.

Vor diesem Hintergrund besteht die Aufgabe der Erfindung in der Bereitstellung eines verbesserten Verfahrens zur Herstellung von substituierten Thien-3yl-sulfonylamino-carbonyltriazolinonen, insbesondere von Thiencarbazone-methyl, d.h. der Verbindung der Formel (I), wobei das verbesserte Verfahren die Herstellung der Zielverbindung Thiencarbazone-methyl in einer hohen Reinheit und Ausbeute ermöglichen soll.Against this background, the object of the invention is to provide an improved process for the preparation of substituted thien-3yl-sulfonylamino-carbonyltriazolinones, in particular thiencarbazone-methyl, ie the compound of the formula (I), the improved process being the preparation of the target compound thiencarbazone -methyl should enable high purity and yield.

Gelöst wird die Aufgabe durch das Verfahren nach Anspruch 1 zur Herstellung der Verbindung der Formel (I)

Figure imgb0001
durch Umsetzung der Verbindung der Formel (II)
Figure imgb0002
mit einem Metallcyanat der Formel (III)

        MeOCN     (III)

, worin Me für Li, Na, K oder, Cs steht mit der Verbindung der Formel (IV)
Figure imgb0003
, wobei die Umsetzung in Gegenwart eines Imidazols der Formel (V)
Figure imgb0004
, worin der Rest R1 für ein unsubstitutiertes (C1-C12)-Alkyl oder für ein unsubstitutiertes Benzyl steht, erfolgt.The object is achieved by the process according to claim 1 for the preparation of the compound of the formula (I)
Figure imgb0001
by reacting the compound of formula (II)
Figure imgb0002
with a metal cyanate of the formula (III)

MeOCN (III)

where Me stands for Li, Na, K or, Cs with the compound of formula (IV)
Figure imgb0003
, where the reaction in the presence of an imidazole of the formula (V)
Figure imgb0004
, in which the radical R1 is an unsubstituted (C 1 -C 12 ) -alkyl or an unsubstituted benzyl.

Überraschend wurde im Zusammenhang mit dem erfindungsgemäßen Verfahren gefunden, dass der Einsatz von alkylsubstitutierten Imidazolen, insbesondere von N-Alkylimidazolen die Herstellung von substituierten Thien-3yl-sulfonylaminocarbonyl-triazolinonen, insbesondere die Herstellung von Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylat(Thiencarbazone-methyl) in einer besonders hohen Reinheit und Ausbeute ermöglicht.Surprisingly, it was found in connection with the process according to the invention that the use of alkyl-substituted imidazoles, in particular of N-alkylimidazoles, the production of substituted thien-3yl-sulfonylaminocarbonyl-triazolinones, in particular the production of methyl 4 - [(4,5-dihydro-3 Methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] -5-methylthiophenes-3-carboxylate (thiencarbazone-methyl) in a particularly high purity and yield enables.

Der Erfindung liegt somit die Erkenntnis zugrunde, dass sich die Verbindung der Formel (I) Thiencarbazone-methyl unter bestimmten Bedingungen, nämlich in Gegenwart einer in 1-Position substituierten Imidazol-Base oder in Gegenwart einer Basen-Mischung, welche eine in 1-Position substituierte Imidazol-Base (N-Alkylimidazol) enthält, direkt aus 4-Methoxycarbonyl-2-methyl-thiophen-3-sulfonsäurechlorid (Verbindung der Formel (II)) mit einer hohen Reinheit und Ausbeute herstellbar ist.The invention is thus based on the finding that the compound of the formula (I) thiencarbazone-methyl under certain conditions, namely in the presence of an imidazole base substituted in the 1-position or in the presence of a base mixture which has a 1-position substituted imidazole base (N-alkylimidazole) contains, can be prepared directly from 4-methoxycarbonyl-2-methyl-thiophene-3-sulfonic acid chloride (compound of formula (II)) with a high purity and yield.

Reaktionsschema:

Figure imgb0005
Reaction scheme:
Figure imgb0005

Das vorstehende Reaktionsschema zeigt, dass bei Durchführung der Reaktion als Eintopfsynthese zu Reaktionsbeginn ein 4-Komponenten-System vorliegt.The above reaction scheme shows that when the reaction is carried out as a one-pot synthesis, a 4-component system is present at the start of the reaction.

Im Fall einer zweistufigen Reaktionsführung wird das Edukt 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on der Formel (IV) erst nach Bildung des Sulfonylisocyanats aus Verbindungen der Formeln (II) und (III) in Gegenwart eines N-Alkylimidazols der Formel (V) zu dem Gemisch zugegeben.In the case of a two-stage reaction, the starting material 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one of the formula (IV) is only added after the sulfonyl isocyanate has been formed from compounds of the formulas ( II) and (III) are added to the mixture in the presence of an N-alkylimidazole of the formula (V).

Die Synthese der Edukte, d.h. die Synthese der Verbindungen der Formel (II) und (IV) im vorgenannten Reaktionsschema, ist in DE 19933260 A1 offenbart. Die Verbindungen der Formel (III) und (V) sind kommerziell erhältlich.The synthesis of the starting materials, ie the synthesis of the compounds of the formulas (II) and (IV) in the aforementioned reaction scheme, is in DE 19933260 A1 disclosed. The compounds of the formula (III) and (V) are commercially available.

Es wird vermutet, dass die in 1-Position durch einen Alkylrest substituierten Imidazole (N-Alkylimidazole) bei der Bildung des Sulfonylisocyanats besonders gut als Aktivatoren (= Aktivierungsmittel) und/oder Stabilisatoren bei der Bildung des Sulfonylisocyanats wirken.It is assumed that the imidazoles (N-alkylimidazoles) substituted in the 1-position by an alkyl radical act particularly well as activators (= activating agents) and / or stabilizers in the formation of the sulfonyl isocyanate in the formation of the sulfonyl isocyanate.

Der Kern der vorliegenden Erfindung betrifft jedoch die überraschende Erkenntnis, dass das Metallcyanat mit der Sulfonylgruppe der jeweiligen Thiophenverbindung (die im vorstehenden Schema mit dem Methyl-4-(chlorsulfonyl)-5-methylthiophen-3-carboxylate der Formel (II)) in Gegenwart eines N-Alkylimidazols der Formel (V) selektiv zu einem Sulfonylisocyanat reagiert, und dass sich aus diesem anschließend das substituierte Thien-3yl-sulfonylamino-carbonyltriazolinon (im vorstehenden Reaktionsschema die Zielverbindung Thiencarbazone-methyl (I)) bildet.The core of the present invention, however, relates to the surprising finding that the metal cyanate with the sulfonyl group of the respective thiophene compound (in the above scheme with the methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate of the formula (II)) in the presence of an N-alkylimidazole of the formula (V) reacts selectively to form a sulfonyl isocyanate, and that the substituted thien-3yl-sulfonylamino-carbonyltriazolinone (in the above reaction scheme, the target compound thiencarbazone-methyl (I)) is then formed from this.

Die unerwartete Selektivität der im Schema dargestellten Reaktion besteht darin, dass das Triazolinon (IV) erst nach Bildung des Sulfonylisocyanats mit demselben weiter zu Thiencarbazone-methyl, reagiert.The unexpected selectivity of the reaction shown in the scheme consists in the fact that the triazolinone (IV) only reacts further with the sulfonyl isocyanate to form thiencarbazone-methyl after formation of the sulfonyl isocyanate.

Außerdem ist im Hinblick auf den Einsatz eines Metallcyanats bei einer chemischen Reaktion ganz allgemein zu bedenken, dass Metallcyanate starke Basen sind (Natriumcyanat (NaOCN) hat z.B. einen pH von 10). Zugleich wirken Metallcyanate als O-Nukleophile.In addition, with regard to the use of a metal cyanate in a chemical reaction, it should be considered in general that metal cyanates are strong bases (sodium cyanate (NaOCN), for example, has a pH of 10). At the same time, metal cyanates act as O nucleophiles.

In Gegenwart eines N-Alkylimidazols, insbesondere in Gegenwart von N-Methylimidazol, wirkt sich die O-Nukleophilie der erfindungsgemäß eingesetzten Metallcyanate überraschenderweise aber gerade nicht auf den Verlauf der vorliegenden Reaktion, d.h. deren Ausbeute und deren Selektivität aus.In the presence of an N-alkylimidazole, in particular in the presence of N-methylimidazole, the O-nucleophilicity of the metal cyanates used according to the invention surprisingly has no effect on the course of the present reaction, i.e. its yield and selectivity.

Das gilt nicht für den Einsatz anderer basischer Stickstoffverbindungen wie Pyridine, Picoline oder 4-(Dimethylamino)-pyridin (DMAP), die als klassische Aktivatoren für, zum Beispiele, Carbonsäurehalogenide anzusehen sind. Das Gleiche gilt für den Einsatz von anorganischen Basen wie K2CO3 oder Kalium-tert-butylat (KOtBut) die sich ebenfalls als nicht geeignet erwiesen haben.This does not apply to the use of other basic nitrogen compounds such as pyridines, picolines or 4- (dimethylamino) pyridine (DMAP), which are to be regarded as classic activators for, for example, carboxylic acid halides. The same applies to the use of inorganic bases such as K 2 CO 3 or potassium tert-butoxide (KOtBut), which have also proven to be unsuitable.

So wurde durch Beispiel belegt, dass die Thiencarbazone-methyl-Ausbeute bei Anwendung des erfindungsgemäßen Verfahrens im Vergleich zur Durchführung der Reaktion unter Einsatz anderer alternativer basischer Stickstoffverbindungen unerwartet hoch ist.It was demonstrated by example that the thiencarbazone-methyl yield when using the process according to the invention is unexpectedly high compared to carrying out the reaction using other alternative basic nitrogen compounds.

Bevorzugt ist die Durchführung des erfindungsgemäßen Verfahrens in Gegenwart eines Imidazols der Formel (V), worin der Rest R1 ein unsubstituiertes (C1-C6)-Alkyl, oder ein unsubstituiertes Benzyl ist. Die Durchführung des Verfahrens in Gegenwart eines Imidazols der Formel (V), worin der Rest R1 ein substituiertes (C1-C6)-Alkyl, oder ein substituiertes Benzyl ist nicht bevorzugt, liegt jedoch ebenfalls im Rahmen der Erfindung.It is preferred to carry out the process according to the invention in the presence of an imidazole of the formula (V) in which the radical R 1 is an unsubstituted (C 1 -C 6 ) -alkyl or an unsubstituted benzyl. Carrying out the process in the presence of an imidazole of the formula (V) in which the radical R 1 is a substituted (C 1 -C 6 ) -alkyl or a substituted benzyl is not preferred, but is likewise within the scope of the invention.

Besonders bevorzugt ist die Durchführung des erfindungsgemäßen Verfahrens in Gegenwart eines Imidazols der Formel (V), worin der Rest R1 ein unsubstituiertes (C1-C4)-Alkyl ist. Unverzweigte (C1-C4)-Alkyl, d.h. Methyl, Ethyl, n-Propyl oder n-Butyl für R1 sind ganz besonders bevorzugt.It is particularly preferred to carry out the process according to the invention in the presence of an imidazole of the formula (V) in which the radical R 1 is an unsubstituted (C 1 -C 4 ) -alkyl. Unbranched (C 1 -C 4 ) -alkyl, ie methyl, ethyl, n-propyl or n-butyl for R 1, are very particularly preferred.

Am meisten bevorzugt ist die Durchführung des erfindungsgemäßen Verfahrens in Gegenwart von N-Methylimidazol (NMI), d.h. wenn. der Rest R1 in Formel (V) für Methyl steht.It is most preferred to carry out the process according to the invention in the presence of N-methylimidazole (NMI), ie when. the radical R 1 in formula (V) represents methyl.

Zur Herstellung der Verbindung der Formel (I) werden bei dem erfindungsgemäßen Verfahren die Reagenzien bevorzugt äquimolar oder im Überschuss eingesetzt.To prepare the compound of the formula (I) in the process according to the invention, the reagents are preferably used in equimolar amounts or in excess.

In allgemein werden je Mol Sulfonsäurechlorid, d.h. der Verbindung der Formel (II) 1 bis 2,5 Mol, bevorzugt 1 bis 2 Mol, besonders bevorzugt 1 bis 1,8 Mol des Metallcyanats der Formel MeOCN (III) eingesetzt. Aber auch der Einsatz größerer Überschüsse der Verbindung der Formel (III) liegt im Rahmen der Erfindung.In general, 1 to 2.5 mol, preferably 1 to 2 mol, particularly preferably 1 to 1.8 mol, of the metal cyanate of the formula MeOCN (III) are used per mole of sulfonic acid chloride, ie the compound of the formula (II). However, the use of relatively large excesses of the compound of the formula (III) is also within the scope of the invention.

In einer bevorzugten Ausführungsform steht Me in Verbindungen der Formel MeOCN (III) für Na oder für K. Das bei dem erfindungsgemäßen Verfahren am meisten bevorzugte Metallcyanat ist NaOCN. Weiterhin werden im Allgemeinen je Mol Sulfonsäurechlorid, d.h. von der Verbindung der Formel (IV) (5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on) ebenfalls 1 bis 2 Mol, bevorzugt 1 bis 1,5 Mol, besonders bevorzugt 1 bis 1,1 Mol eingesetzt.In a preferred embodiment, Me in compounds of the formula MeOCN (III) stands for Na or for K. The most preferred metal cyanate in the process according to the invention is NaOCN. Furthermore, per mole of sulfonic acid chloride, ie of the compound of the formula (IV) (5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one), there are also 1 to 2 Mol, preferably 1 to 1.5 mol, particularly preferably 1 to 1.1 mol.

Aber auch der Einsatz größerer Überschüsse der Verbindung der Formel (IV) liegt im Rahmen der Erfindung.However, the use of relatively large excesses of the compound of the formula (IV) is also within the scope of the invention.

Die Durchführung des Verfahrens erfolgt in einem organischen Lösungsmittel, wobei unpolare und polare Lösungsmittel geeignet sind.The process is carried out in an organic solvent, with non-polar and polar solvents being suitable.

Als unpolare Lösungsmittel kommen Toluol, Chlorbenzol, Xylol, Methyl-tert-butylether, Methylisopropylether, Ethylacetat, Isopropylacetat und Butylacetat in Frage.Suitable non-polar solvents are toluene, chlorobenzene, xylene, methyl tert-butyl ether, methyl isopropyl ether, ethyl acetate, isopropyl acetate and butyl acetate.

Besonders bevorzugte polare Lösungsmittel sind ausgewählt aus der Gruppe bestehend aus Acetonitril, Butyronitril, Tetrahydrofuran (THF), Methyl-THF, Dimethoxyethan, Sulfolan, Dimethylformamid und Dimethylacetamid.Particularly preferred polar solvents are selected from the group consisting of acetonitrile, butyronitrile, tetrahydrofuran (THF), methyl-THF, dimethoxyethane, sulfolane, dimethylformamide and dimethylacetamide.

Am meisten bevorzugt als Lösungsmittel sind Acetonitril und THF.Most preferred solvents are acetonitrile and THF.

Auch Gemische von verschiedenen Lösungsmitteln können eingesetzt werden.Mixtures of different solvents can also be used.

Bevorzugt erfolgt die Umsetzung der Edukte in einem Temperaturbereich von 20° bis 110° über eine Dauer (Reaktionszeit, Reaktionsdauer) von 3 Stunden bis 24 Stunden.The reactants are preferably reacted in a temperature range from 20 ° to 110 ° over a period (reaction time, reaction time) of 3 hours to 24 hours.

Ganz besonders bevorzugt ist die Umsetzung der Edukte in einem Temperaturbereich von 30° bis 90°. Am meisten bevorzugt erfolgt die Umsetzung der Edukte in einem Temperaturbereich von 50° bis 80°.The reaction of the starting materials in a temperature range from 30 ° to 90 ° is very particularly preferred. Most preferably, the reactants are reacted in a temperature range from 50 ° to 80 °.

Ein weiterer Aspekt der Erfindung betrifft die Verwendung eines Imidazols der Formel (V)

Figure imgb0006
, worin der Rest R1 für ein unsubstitutiertes (C1-C12)-Alkyl oder für ein unsubstitutiertes Benzyl steht, zur Herstellung der Verbindung der Formel (I)
Figure imgb0007
Another aspect of the invention relates to the use of an imidazole of the formula (V)
Figure imgb0006
, in which the radical R 1 is an unsubstituted (C 1 -C 12 ) -alkyl or an unsubstituted benzyl, for the preparation of the compound of the formula (I)
Figure imgb0007

Bevorzugt ist die Verwendung eines Imidazols der Formel (V), worin R1 ein unsubstituiertes (C1-C4)-Alkyl steht.The use of an imidazole of the formula (V) in which R 1 is an unsubstituted (C 1 -C 4 ) -alkyl is preferred.

Besonders bevorzugt ist die Verwendung eines Imidazols der Formel (V), worin R1 für ein unverzweigtes und unsubstituiertes (C1-C4)-Alkyl, d.h. für Methyl, Ethyl, n-Propyl oder n-Butyl steht.It is particularly preferred to use an imidazole of the formula (V) in which R 1 is an unbranched and unsubstituted (C 1 -C 4 ) -alkyl, ie, methyl, ethyl, n-propyl or n-butyl.

Am meisten bevorzugt ist die Verwendung eines Imidazols der Formel (V), worin R1 für Methyl steht.Most preferred is the use of an imidazole of the formula (V) in which R 1 is methyl.

BEISPIELE:EXAMPLES:

Das erfindungsgemäße Herstellungsverfahren kann als Eintopfverfahren oder als zweistufige Reaktion durchgeführt werden.The production process according to the invention can be carried out as a one-pot process or as a two-stage reaction.

Beim Eintopfverfahren werden alle Chemikalien in einem organischen Lösemittel gemischt und dann unter Rühren erhitzen. Um die Exothermie der Reaktion besser zu kontrollieren, ist es auch empfehlenswert, die Reagenzien der Formel (III), (IV) und (V) in z. B. Acetonitril vorzulegen, um dann das Sulfonylchlorid der Formel (II) als Lösung bei der Rektionstemperatur langsam hinzu zu dosieren.In the one-pot process, all chemicals are mixed in an organic solvent and then heated while stirring. In order to better control the exothermicity of the reaction, it is also advisable to use the reagents of the formula (III), (IV) and (V) in e.g. B. to submit acetonitrile in order to then slowly add the sulfonyl chloride of the formula (II) as a solution at the reaction temperature.

Während der Reaktion fällt der Wirkstoff oder dessen Salz aus dem Reaktionsgemisch aus und kann einfach ab filtriert werden.During the reaction, the active ingredient or its salt precipitates out of the reaction mixture and can simply be filtered off.

Besonders vorteilhaft ist es, am Ende der Reaktion eine anorganische Base wie z.B. LiOH, K2CO3, NaHCO3, NaOH, , Na2CO3, CaCO3 oder KOH zu dem Gemisch zuzusetzen, um den Wirkstoff als unlösliches Li, Na, K oder Ca-Salz zu isolieren. Bevorzugt ist die Verwendung von NaHCO3. Auf diese Weise gelingt die Isolierung des Wirkstoffes in sehr hoher Reinheit.It is particularly advantageous to add an inorganic base such as LiOH, K 2 CO 3 , NaHCO 3 , NaOH, Na 2 CO 3 , CaCO 3 or KOH to the mixture at the end of the reaction in order to convert the active ingredient as insoluble Li, Na, Isolate K or Ca salt. The use of NaHCO 3 is preferred. In this way, the active ingredient can be isolated with a very high degree of purity.

Die Menge der einzusetzenden Base hängt davon ab, wieviel Metallcyanat bei Durchführung der Reaktion eingesetzt wird. Bei Einsatz von nur 1 Äquivalent (Eq) NaOCN ist dann entsprechend 1 Eq. Base notwendig, um den Wirkstoff komplett in das Salz zu überführen (Beispiel 1). Setzt man beispielsweise 2 Eq des Metallcyanats, z.B. 2 Eq NaOCN, zur Durchführung der Reaktion ein, so ist keine zusätzliche Base notwendig (vgl. Beispiel 3).The amount of base to be used depends on how much metal cyanate is used when carrying out the reaction. If only 1 equivalent (eq) of NaOCN is used, 1 eq. Of base is then required to completely convert the active ingredient into the salt (example 1). If you set for example 2 eq of the metal cyanate, for example 2 eq NaOCN, to carry out the reaction, no additional base is necessary (cf. Example 3).

Durch Behandlung des Salzes mit einer Säure (z.B. HCl, H2SO4) wird der Wirkstoff freigesetzt und nach der Filtration isoliert.Treatment of the salt with an acid (eg HCl, H 2 SO 4 ) releases the active ingredient and isolates it after filtration.

Es ist auch möglich, zuerst die Verbindung der Formel (II) mit MeOCN in Gegenwart der Verbindung der Formel (V) umzusetzen, um das Sulfonylisocynat der Formel (VI) herzustellen. In einem zweiten Schritt wird dann das Sulfonylisocyanat, ggf. ohne vorherige Isolierung, mit 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on der Formel (IV) umgesetzt.It is also possible to first react the compound of the formula (II) with MeOCN in the presence of the compound of the formula (V) in order to prepare the sulfonyl isocyanate of the formula (VI). In a second step, the sulfonyl isocyanate is then reacted with 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one of the formula (IV), if necessary without prior isolation.

Die Analyse, Identifizierung und Gehaltsbestimmung von Sulfonylisocynat nach dem Schritt 1 basiert auf der Derivatisierung mit Methanol zum entsprechenden Carbamat der Formel (VII).

Figure imgb0008
The analysis, identification and determination of the content of sulfonyl isocyanate after step 1 is based on the derivatization with methanol to give the corresponding carbamate of the formula (VII).
Figure imgb0008

Falls notwendig, kann das Isocyanat isoliert und durch Destillation im Vakuum gereinigt werden. TABELLE 1 Tabellarischer Vergleich der Ausbeuten aufgrund LC-Analytik bei Einsatz verschiedener Reaktionshilfsmittel zur Herstellung von Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylat (Thiencarbazone-methyl), in Acetonitrile, NaOCN 2 Eq. Vergleich No. Menge Aktivator / Mol. Eq Zeit (Std)/T°C Zielprodukt LC, Area % 1 2-Methylpyridin / 1 12/80 26 2 3-Methylpyridin / 1 12/80 36 3 3-Methylpyridin / 0.1 12/80 25 4 2-methyl-5-ethylpyridin / 1 12/80 27 5 2-Methyl-5-ethylpyridin / 5 12/80 29 6 p-Dimethylaminopyridin / 0,5 12/80 34 7 2,6-dimethylpyridin / 1 12(80) 37 8 Tributylamine / 1 12(60) 5 9 KOtBut / 1 12 (80) 0 10 N-Butylimidazol/1 12(80) 84 11 N-Methylimidazol / 1 12(80) 92 12 N-Methylimidazol / 0,8 12(80) 91 If necessary, the isocyanate can be isolated and purified by distillation in vacuo. TABLE 1 Tabular comparison of the yields based on LC analysis when using different reaction auxiliaries for the preparation of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1 -yl) carbonyl) sulfamoyl] -5-methylthiophenes-3-carboxylate (thiencarbazone-methyl), in acetonitrile, NaOCN 2 eq. Comparison No. Amount of activator / mole eq Time (hrs) / T ° C Target product LC, area% 1 2-methylpyridine / 1 12/80 26th 2 3-methylpyridine / 1 12/80 36 3 3-methylpyridine / 0.1 12/80 25th 4th 2-methyl-5-ethylpyridine / 1 12/80 27 5 2-methyl-5-ethylpyridine / 5 12/80 29 6 p-dimethylaminopyridine / 0.5 12/80 34 7th 2,6-dimethylpyridine / 1 12 (80) 37 8th Tributylamine / 1 12 (60) 5 9 KOtBut / 1 12 (80) 0 10 N-butylimidazole / 1 12 (80) 84 11 N-methylimidazole / 1 12 (80) 92 12th N-methylimidazole / 0.8 12 (80) 91

Die oben stehende Tabelle belegt, dass die Thiencarbazone-methyl-Ausbeute bei Anwendung des erfindungsgemäßen Verfahrens bei Einsatz von N-Butylimidazol und N-Methylimidazol im Vergleich zu anderen Stickstoffbasen unerwartet hoch ist. Dagegen ist beim vergleichenden Einsatz der Stickstoffbase Tributylamin das durch Flüssigchromatographie (LC) nachweisbare Zielprodukt Thiencarbazone-methyl in einem niedrigen %-Bereich. Bei Einsatz des Säurebindemittels Kalium-tert-butylat (KOtBut) ist ein Produktnachweis gar nicht möglich.The table above shows that the thiencarbazone-methyl yield when using the method according to the invention when using N-butylimidazole and N-methylimidazole is unexpectedly high compared to other nitrogen bases. In contrast, when comparing the nitrogen base tributylamine, the target product thiencarbazone-methyl, which can be detected by liquid chromatography (LC), is in a low% range. If the acid binding agent potassium tert-butylate (KOtBut) is used, product verification is not possible at all.

SYNTHESEBEISPIELESYNTHESIS EXAMPLES Beispiel 1example 1 Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylat (Eintopfverfahren)Methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] -5-methylthiophene-3-carboxylate (One-pot process)

25.4 g von Methyl-4-(chlorsulfonyl)-5-methylthiophen-3-carboxylat, 6,5 g NaOCN, 12,9 g N-Methylimidazol und 12,9 g 5-Methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on wird in 200 ml Acetonitril vorgelegt und auf 70°C erhitzt. Das Gemisch wurde unter Rühren 12 Std bei dieser Temperatur erhitzt und auf 20°C abgekühlt.25.4 g of methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate, 6.5 g NaOCN, 12.9 g N-methylimidazole and 12.9 g 5-methoxy-4-methyl-2,4-dihydro -3H-1,2,4-triazol-3-one is placed in 200 ml of acetonitrile and heated to 70.degree. The mixture was heated at this temperature for 12 hours with stirring and cooled to 20 ° C.

Dem Gemisch wurden 8,5 g NaHCO3 zugesetzt und die Suspension wurde 3 Std bei 20°C nachgerührt. Der Niederschlag wurde abfiltriert, mit 50 ml 10-iger % HCl und 100 ml Wasser gewaschen und bei 50°C getrocknet. Man erhielt 31,6 g des_Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylats, 80 % der Theorie mit einem Schmelzpunkt von 201°C, und einer Reinheit von 99 %.8.5 g of NaHCO 3 were added to the mixture and the suspension was stirred at 20 ° C. for 3 hours. The precipitate was filtered off, washed with 50 ml of 10% HCl and 100 ml of water and dried at 50.degree. 31.6 g was obtained des_Methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] -5 methylthiophene-3-carboxylate, 80% of theory with a melting point of 201 ° C, and a purity of 99%.

Beispiel 2Example 2 Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylat (Eintopfverfahren)Methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] -5-methylthiophene-3-carboxylate (One-pot process)

25.4 g. von Methyl-4-(chlorsulfonyl)-5-methylthiophen-3-carboxylat, 11,7 g NaOCN, 8,2 g N-Methylimidazol und 12,9 g 5-Methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on wird in 220 ml Acetonitril vorgelegt und auf 70°C erhitzt. Das Gemisch wurde unter Rühren 18 Std bei dieser Temperatur erhitzt und auf 20°C abgekühlt. Dem Gemisch wurden 1,7 g NaHCO3 zugesetzt und die Suspension wurde 2 Std bei 20°C nachgerührt. Das Reaktionsgemisch wurde auf 60°C erhitzt, der Niederschlag wurde ab filtriert und mit 50 ml Acetonitril gewaschen. Danach wurde der Niederschlag mit 70 ml 20-iger % H2SO4, 100 ml heißem (70°C) Wasser und 50 ml Acetone gewaschen und bei 50°C getrocknet. Man erhielt 31,4 g des Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylats, 79 % der Theorie mit einer Reinheit von 98 %.25.4 g. of methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate, 11.7 g NaOCN, 8.2 g N-methylimidazole and 12.9 g 5-methoxy-4-methyl-2,4-dihydro-3H -1,2,4-triazol-3-one is placed in 220 ml of acetonitrile and heated to 70.degree. The mixture was heated with stirring at this temperature for 18 hours and cooled to 20 ° C. 1.7 g of NaHCO 3 were added to the mixture and the suspension was stirred at 20 ° C. for 2 hours. The reaction mixture was heated to 60 ° C., the precipitate was filtered off and washed with 50 ml of acetonitrile. The precipitate was then washed with 70 ml of 20% H 2 SO 4 , 100 ml of hot (70 ° C.) water and 50 ml of acetone and dried at 50 ° C. This gave 31.4 g of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] - 5-methylthiophen-3-carboxylate, 79% of theory with a purity of 98%.

Beispiel 3Example 3 Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylat (Eintopfverfahren)Methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] -5-methylthiophene-3-carboxylate (One-pot process)

25.4 g von Methyl-4-(chlorsulfonyl)-5-methylthiophen-3-carboxylat, 13 g NaOCN, 12,9 g N-Methylimidazol und 12,9 g 5-Methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on wird in 200 ml Acetonitril vorgelegt und auf 70°C erhitzt. Das Gemisch wurde unter Rühren 12 Std bei dieser Temperatur erhitzt und auf 20°C abgekühlt.25.4 g of methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate, 13 g NaOCN, 12.9 g N-methylimidazole and 12.9 g 5-methoxy-4-methyl-2,4-dihydro-3H -1,2,4-triazol-3-one is in 200 ml Submitted acetonitrile and heated to 70 ° C. The mixture was heated at this temperature for 12 hours with stirring and cooled to 20 ° C.

Der Niederschlag wurde abfiltriert, mit 50 ml 10-iger % HCl und 100 ml Wasser gewaschen und bei 50°C getrocknet. Man erhielt 33,6 g des Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylats, 84,4 % der Theorie mit einer Reinheit von 98 %.The precipitate was filtered off, washed with 50 ml of 10% HCl and 100 ml of water and dried at 50.degree. This gave 33.6 g of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] - 5-methylthiophen-3-carboxylate, 84.4% of theory with a purity of 98%.

Beispiel 4Example 4 Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylat (Zweistufen-Verfahren)Methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] -5-methylthiophene-3-carboxylate (Two-step process)

25.4 g von Methyl-4-(chlorsulfonyl)-5-methylthiophen-3-carboxylate, 6,5 g NaOCN, 12,9 g N-Methylimidazol wurden in 150 ml Acetonitril vorgelegt und das Gemisch 4 Std bei 50°C erhitzt. Die Suspension wurde unter Argon über eine Glassfritte filtriert und dem Filtrat 12.5 g 5-Methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on zugegeben. Anschließend wurde das Gemisch 8 Std bei 70°C erhitzt und auf 20°C abgekühlt.25.4 g of methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate, 6.5 g of NaOCN, 12.9 g of N-methylimidazole were placed in 150 ml of acetonitrile and the mixture was heated at 50 ° C. for 4 hours. The suspension was filtered through a glass frit under argon and 12.5 g of 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one were added to the filtrate. The mixture was then heated at 70 ° C. for 8 hours and cooled to 20 ° C.

Dem Gemisch wurden 8 g NaHCO3 und 1 ml Wasser zugesetzt und die Suspension wurde 3 Std nachgerührt. Der Niederschlag wurde abfiltriert, mit 50 ml 10 %-iger HCl und 100 ml Wasser gewaschen und bei 50°C getrocknet. Man erhielt 29,6 g des Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylats 75,6 % der Theorie mit einem Schmelzpunkt 201°C und einer Reinheit von >99 %.8 g of NaHCO 3 and 1 ml of water were added to the mixture and the suspension was stirred for 3 hours. The precipitate was filtered off, washed with 50 ml of 10% HCl and 100 ml of water and dried at 50.degree. This gave 29.6 g of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] - 5-methylthiophene-3-carboxylate 75.6% of theory with a melting point of 201 ° C. and a purity of> 99%.

Beispiel 5Example 5 Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylat (Zweistufen-Verfahren)Methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] -5-methylthiophene-3-carboxylate (Two-step process)

25.4 g von Methyl-4-(chlorsulfonyl)-5-methylthiophen-3-carboxylate, 11,7 g NaOCN, 12,3 g N-Methylimidazol wurden in 150 ml Acetonitril vorgelegt und das Gemisch 4 Std bei 50°C erhitzt. Die Suspension wurde unter Argon über eine Glassfritte filtriert und dem Filtrat 12.5 g 5-Methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-on zugegeben. Anschließend wurde das Gemisch 12 Std bei 70°C erhitzt und auf 20°C abgekühlt.25.4 g of methyl 4- (chlorosulfonyl) -5-methylthiophene-3-carboxylate, 11.7 g of NaOCN, 12.3 g of N-methylimidazole were placed in 150 ml of acetonitrile and the mixture was heated at 50 ° C. for 4 hours. The suspension was filtered through a glass frit under argon and 12.5 g of 5-methoxy-4-methyl-2,4-dihydro-3H-1,2,4-triazol-3-one were added to the filtrate. The mixture was then heated at 70 ° C. for 12 hours and cooled to 20 ° C.

Dem Gemisch wurden 1.7 g NaHCO3 und 1 ml Wasser zugesetzt und die Suspension wurde 3 Std nachgerührt. Der Niederschlag wurde abfiltriert, mit 50 ml 10 %-iger HCl und 100 ml heißem Wasser gewaschen und bei 50°C getrocknet. Man erhielt 30,5 g des Methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1H-1,2,4-triazole-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylats 77 % der Theorie mit einer Reinheit von 98 %.1.7 g of NaHCO 3 and 1 ml of water were added to the mixture and the suspension was stirred for 3 hours. The precipitate was filtered off, washed with 50 ml of 10% HCl and 100 ml of hot water and dried at 50.degree. This gave 30.5 g of methyl 4 - [(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1 H -1,2,4-triazole-1-yl) carbonyl) sulfamoyl] - 5-methylthiophen-3-carboxylate 77% of theory with a purity of 98%.

Beispiel 6Example 6 Methyl 4-(methoxycarbonylsulfamoyl)-5-methyl-thiophen-3-carboxylatMethyl 4- (methoxycarbonylsulfamoyl) -5-methyl-thiophene-3-carboxylate

25.4 g von Methyl-4-(chlorsulfonyl)-5-methylthiophene-3-carboxylat, 6,5 g NaOCN, 12,9 g N-Methylimidazol wurden in 150 ml Acetonitril vorgelegt und das Gemisch 4 Std bei 50°C erhitzt. Die Suspension wurde unter Argon über eine Glassfritte filtriert und mit 30 ml Methanol versetzt. Nach 1 Std wurde die Lösung komplett eingeengt und der Niederschlag mit Waser gewaschen und getrocknet. Man erhielt 24 g Methyl 4-(methoxycarbonylsulfamoyl)-5-methyl-thiophen-3-carboxylat (1H NMR: (d6 DMSO) 2,72 (s), 3,62 (s), 3,79 (s), 8.01 (s), 12.01 (s) ppm).25.4 g of methyl 4- (chlorosulfonyl) -5-methylthiophen-3-carboxylate, 6.5 g of NaOCN, 12.9 g of N-methylimidazole were placed in 150 ml of acetonitrile and the mixture was heated at 50 ° C. for 4 hours. The suspension was filtered through a glass frit under argon, and 30 ml of methanol were added. After 1 hour, the solution was completely concentrated and the precipitate was washed with water and dried. 24 g of methyl 4- (methoxycarbonylsulfamoyl) -5-methyl-thiophene-3-carboxylate were obtained ( 1 H NMR: (d 6 DMSO) 2.72 (s), 3.62 (s), 3.79 (s) , 8.01 (s), 12.01 (s) ppm).

Claims (15)

  1. Method for preparing the compound of the formula (I)
    Figure imgb0015
    by reacting the compound of the formula (II)
    Figure imgb0016
    with a metal cyanate of the formula (III)

            MeOCN     (III)

    where Me is Li, Na, K or Cs
    and
    with the compound of the formula (IV)
    Figure imgb0017
    wherein the reaction is carried out in the presence of an imidazole of the formula (V)
    Figure imgb0018
    where the radical R1 is an unsubstituted (C1-C12) -alkyl or an unsubstituted benzyl.
  2. Method for preparing compounds of the formula (I) according to Claim 1, characterized in that R1 is an unsubstituted (C1-C6)-alkyl or an unsubstituted benzyl.
  3. Method for preparing compounds of the formula (I) according to Claim 2, characterized in that R1 is an unsubstituted (C1-C4)-alkyl.
  4. Method for preparing compounds of the formula (I) according to Claim 3, characterized in that R1 is methyl, ethyl, n-propyl or n-butyl.
  5. Method for preparing compounds of the formula (I) according to Claim 4, characterized in that R1 is methyl.
  6. Method for preparing compounds of the formula (I) according to any of Claims 1 to 5, characterized in that Me in compounds of the formula MeOCN (III) is Na or K.
  7. Method for preparing compounds of the formula (I) according to any of Claims 1 to 6, characterized in that the reaction is carried out in a polar solvent selected from the group consisting of acetonitrile, butyronitrile, tetrahydrofuran (THF), methyl-THF, dimethoxyethane, sulfolane, dimethylformamide and dimethylacetamide.
  8. Method for preparing compounds of the formula (I) according to any of Claims 1 to 6, characterized in that the reaction is carried out in a solvent mixture consisting of acetonitrile and THF.
  9. Method for preparing compounds of the formula (I) according to any of Claims 1 to 8, characterized in that the reaction of the reactants is conducted
    - in a temperature range of 20° to 110° and
    - in a reaction time of 3 hours to 24 hours.
  10. Method for preparing compounds of the formula (I) according to Claim 9, characterized in that the reaction of the reactants is conducted in a temperature range of 30° to 90°.
  11. Method for preparing compounds of the formula (I) according to Claim 10, characterized in that the reaction of the reactants is conducted in a temperature range of 50° to 80°.
  12. Use of an imidazole of the formula (V)
    Figure imgb0019
    where the radical R1 is an unsubstituted (C1-C12) -alkyl or an unsubstituted benzyl, for a method for preparing the compound of the formula (I)
    Figure imgb0020
    according to any of Claims 1 to 9.
  13. Use of an imidazole of the formula (V) according to Claim 12, characterized in that R1 is an unsubstituted (C1-C4)-alkyl.
  14. Use of an imidazole of the formula (V) according to Claim 13, characterized in that R1 is methyl, ethyl, n-propyl or n-butyl.
  15. Use of an imidazole of the formula (V) according to Claim 14, characterized in that R1 is methyl.
EP18706467.0A 2017-02-23 2018-02-15 Process for the preparation of methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h-1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylate Active EP3585785B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17157615 2017-02-23
PCT/EP2018/053771 WO2018153767A1 (en) 2017-02-23 2018-02-15 Process for the preparation of methyl-4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h-1,2,4-triazole-1-yl)carbonyl)sulphamoyl]-5-methylthiophene-3-carboxylate

Publications (2)

Publication Number Publication Date
EP3585785A1 EP3585785A1 (en) 2020-01-01
EP3585785B1 true EP3585785B1 (en) 2021-01-27

Family

ID=58158923

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18706467.0A Active EP3585785B1 (en) 2017-02-23 2018-02-15 Process for the preparation of methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h-1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylate

Country Status (12)

Country Link
US (1) US10906893B2 (en)
EP (1) EP3585785B1 (en)
JP (1) JP7001699B2 (en)
KR (1) KR102520302B1 (en)
CN (1) CN110352193B (en)
BR (1) BR112019017396B1 (en)
DK (1) DK3585785T3 (en)
ES (1) ES2857821T3 (en)
IL (1) IL268358B (en)
MX (1) MX2019009998A (en)
TW (1) TWI668211B (en)
WO (1) WO2018153767A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024200331A2 (en) 2023-03-29 2024-10-03 Bayer Aktiengesellschaft Method for producing methyl-4-isocyanatosulfonyl-5-methyl-thiophene-3-carboxylate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3139250A1 (en) * 1981-10-02 1983-04-21 Basf Ag, 6700 Ludwigshafen PLANT GROWTH REGULATING AZOLYLALKYL-2,3-DIHYDROBENZOFURANES AND THEIR USE
DE4017338A1 (en) * 1990-05-30 1991-12-05 Bayer Ag SULFONYLATED CARBONIC ACID AMIDES
DE19650196A1 (en) * 1996-12-04 1998-06-10 Bayer Ag Thienylsulfonylamino (thio) carbonyl compounds
DE19933260A1 (en) * 1999-07-15 2001-01-18 Bayer Ag Substituted thien-3-yl-sulfonylamino (thio) carbonyl-triazolin (thi) one
AU2003302106A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
DE102004063192A1 (en) * 2004-12-29 2006-07-13 Bayer Cropscience Ag Process for the preparation of substituted thiophenesulfonyl isocyanates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
JP2020508322A (en) 2020-03-19
JP7001699B2 (en) 2022-01-20
IL268358A (en) 2019-09-26
ES2857821T3 (en) 2021-09-29
DK3585785T3 (en) 2021-03-29
IL268358B (en) 2021-01-31
EP3585785A1 (en) 2020-01-01
CN110352193B (en) 2022-11-11
KR20190121770A (en) 2019-10-28
US20200048234A1 (en) 2020-02-13
TWI668211B (en) 2019-08-11
BR112019017396A2 (en) 2020-03-31
WO2018153767A1 (en) 2018-08-30
BR112019017396B1 (en) 2023-02-14
US10906893B2 (en) 2021-02-02
CN110352193A (en) 2019-10-18
KR102520302B1 (en) 2023-04-10
TW201833088A (en) 2018-09-16
MX2019009998A (en) 2019-11-05

Similar Documents

Publication Publication Date Title
EP0277317A1 (en) Nitro derivatives of 2-iminoimidazolidines and 2-iminotetrahydropyrimidines
EP1616863A1 (en) Process for the preparation of fluorinated aromatic compounds
EP3585785B1 (en) Process for the preparation of methyl 4-[(4,5-dihydro-3-methoxy-4-methyl-5-oxo-1h-1,2,4-triazol-1-yl)carbonyl)sulfamoyl]-5-methylthiophene-3-carboxylate
EP0008057B1 (en) Process for the preparation of n-substituted alpha-haloacetanilides
CH632501A5 (en) METHOD FOR PRODUCING 1-AZOLYL-3,3-DIMETHYL-1-PHENOXY-BUTAN-2-ONEN.
DE69401486T2 (en) Process for the preparation of 2-cyanoimidazole derivatives
EP0726258A1 (en) Process and intermediates for the preparation of triazolinones
DE69411783T2 (en) Process for the preparation of sulfonylurea derivatives
EP0659746B1 (en) Process for the preparation of sulfonylaminocarbonyl-triazolinones
EP3577114B1 (en) Method for the preparation of halogenated imidazopyridine derivatives
EP1833813B1 (en) Method for the production of substituted thiophenesulfonyl isocyanates
DE19904310A1 (en) Process for the preparation of heterocyclic compounds
DE19610785A1 (en) Process for the preparation of substituted aromatic thiocarboxamides
EP0047941B1 (en) Process for the production and purification of phenoxy-azolyl-butanone derivatives
EP2233469B1 (en) Method for coupling halogen-substituted aromatic substances with trialkylsilyl-substituted heteroatom-containing organic compounds
DE3723230A1 (en) Novel triazole derivatives, their preparation and their use
DE3916207A1 (en) METHOD AND NEW INTERMEDIATE PRODUCTS FOR THE PRODUCTION OF TRIAZOLONE DERIVATIVES
DE2332323A1 (en) N-2-aminophenyl N'-alkoxycarbonyl S-alkylisothioureas - prepd. by reacting N-(chloromercaptomethylene)carbamic acid esters with amines
EP0470430A1 (en) Process for the preparation of oxyguanidins
EP0416319A2 (en) Process for the preparation of sulfonylisoureas
WO2018141751A1 (en) Production of n-substituted aromatic hydroxylamine
DE1620093B (en) 1-square bracket on furfurylideneamino square bracket for -hydantoine- or -imidazolidinone and process for their preparation
DE3443597A1 (en) SUBSTITUTED AZOLYLALKYL-PYRIDINYL ETHERS

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20201026

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1358261

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502018003809

Country of ref document: DE

REG Reference to a national code

Ref country code: FI

Ref legal event code: FGE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20210325

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210428

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210427

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210427

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210527

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2857821

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20210929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210527

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502018003809

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20211028

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210215

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210527

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230123

Year of fee payment: 6

Ref country code: FI

Payment date: 20230220

Year of fee payment: 6

Ref country code: ES

Payment date: 20230310

Year of fee payment: 6

Ref country code: DK

Payment date: 20230213

Year of fee payment: 6

Ref country code: CH

Payment date: 20230307

Year of fee payment: 6

Ref country code: AT

Payment date: 20230125

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230126

Year of fee payment: 6

Ref country code: GB

Payment date: 20230119

Year of fee payment: 6

Ref country code: DE

Payment date: 20230117

Year of fee payment: 6

Ref country code: BE

Payment date: 20230125

Year of fee payment: 6

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230503

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230125

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20180215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502018003809

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20240229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210127

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20240301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240215

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 1358261

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240229

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20240215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240215

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240229

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240301

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20240229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240903

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240215

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240229

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240229

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240903

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240215

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20250331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240216